Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the Congressional Budget Office (CBO). In its estimates released Tuesday, CBO said 12.

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions of dollars, according to a new report by the Congressional Budget Office (CBO).

Millions of older Americans who are dealing with obesity could soon get help from Medicare to cover the high costs of weight loss medication, which might reduce their risk of serious heart problems. However,

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs for Medicare, but this could have a big effect on all employers health plans as well.

Aiming to tackle the high risk of heart problems among older Americans with obesity, Medicare is contemplating an expansion of coverage for a weight-loss medication known as semaglutide

The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing standards. WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs,

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over dieting.

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

While medications like Ozempic originally dominated the weight-loss space, Wegovy is another injectable prescription weight-loss drug worth knowing about. When properly prescribed, it's been shown to help people lose weight and keep it off,